Patents Assigned to GlaxoSmithKline LLC
  • Benzimidazole Derivatives As PI3 Kinase Inhibitors
    Publication number: 20130197221
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 1, 2013
    Applicant: GlaxoSmithKline LLC
    Inventor: GlaxoSmithKline LLC
  • Thiazolopyridine sirtuin modulating compounds
    Patent number: 8492401
    Abstract: Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: July 23, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Christopher Oalmann, Jeremy S Disch, Pui Yee Ng, Robert B Perni
  • Chemical compounds
    Patent number: 8492554
    Abstract: Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: July 23, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Pingyun Chen, Ricky Couch, Maosheng Duan, Richard Martin Grimes, Wieslaw Mieczyslaw Kazmierski, Beth Adams Norton, Matthew Tallant
  • Derivatives of Betulin
    Publication number: 20130184263
    Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
    Type: Application
    Filed: December 14, 2012
    Publication date: July 18, 2013
    Applicant: GlaxoSmithKline LLC
    Inventor: GlaxoSmithKline LLC
  • 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors
    Patent number: 8486977
    Abstract: The present invention relates to substituted triazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: July 16, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Anne Marie Jeanne Bouillot, Alain Laroze, Lionel Trottet
  • Combination of BRAF and VEGF Inhibitors
    Publication number: 20130172378
    Abstract: A novel combination comprising the VEGFR inhibitor 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-(3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl)-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of VEGFR and/or B-Raf is beneficial.
    Type: Application
    Filed: September 2, 2011
    Publication date: July 4, 2013
    Applicant: GlaxoSmithKline LLC
    Inventor: Rakesh Kumar
  • Method of treating thrombocytopenia
    Patent number: 8476249
    Abstract: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: July 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Connie L. Erickson-Miller, Michael Arning
  • CHEMICAL COMPOUNDS
    Publication number: 20130165415
    Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
    Type: Application
    Filed: February 19, 2013
    Publication date: June 27, 2013
    Applicants: GLAXOSMITHKLINE LLC, SHIONOGI & CO., LTD.
    Inventors: SHIONOGI & CO., LTD., GLAXOSMITHKLINE LLC
  • Calcilytic Compounds
    Publication number: 20130158114
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: February 11, 2013
    Publication date: June 20, 2013
    Applicant: GlaxoSmithKline, LLC
    Inventor: GlaxoSmithKline, LLC
  • Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors
    Publication number: 20130157977
    Abstract: This invention relates to the use of benzimidazole boronic acid derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazole boronic acids in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazole boronic acid compounds for treating cancer.
    Type: Application
    Filed: November 12, 2012
    Publication date: June 20, 2013
    Applicant: GlaxoSmithKline LLC
    Inventor: GlaxoSmithKline LLC
  • NOVEL COMPOUNDS
    Publication number: 20130150383
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Application
    Filed: February 6, 2013
    Publication date: June 13, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Ivan Leo PINTO, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL
    Patent number: 8461364
    Abstract: This invention provides, among other things, polymorphs of the hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: June 11, 2013
    Assignees: GlaxoSmithKline LLC, Anacor Pharmaceuticals, Inc.
    Inventors: Conrad Wheeler, Dan Todd, Pingyun Chen, Beth A. Norton
  • Fast release paracetamol tablets
    Patent number: 8461210
    Abstract: A pharmaceutical composition such as a swallow tablet or capsule formulation is described comprising paracetamol, calcium carbonate, at least one binding agent and at least one disintegrating agent in the form of a granulate, optionally combined with one or more pharmaceutically acceptable extragranular components.
    Type: Grant
    Filed: April 3, 2007
    Date of Patent: June 11, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventor: Hemant H. Alur
  • Benzene Sulfonamide Thiazole And Oxazole Compounds
    Publication number: 20130144055
    Abstract: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    Type: Application
    Filed: January 31, 2013
    Publication date: June 6, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: George Adjabeng, Jerry Leroy Adams, Scott Howard Dickerson, Keith Hornberger, Neil W. Johnson, Kevin Kuntz, Kimberly Petrov, Jeffrey M. Ralph, Tara Renae Rheault, Gregory Schaaf, John Stellwagen, Xinrong Tian, David E. Uehling, Alex G. Waterson, Brian Wilson
  • Methods for Treating Degenerative Diseases/Injuries
    Publication number: 20130137736
    Abstract: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.
    Type: Application
    Filed: January 24, 2013
    Publication date: May 30, 2013
    Applicant: GlaxoSmithKline LLC
    Inventor: GlaxoSmithKline LLC
  • TRPV4 antagonists
    Patent number: 8450484
    Abstract: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: May 28, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventors: Michael Jonathan Bury, Mui Cheung, Hilary Schenck Eidam, Ryan Michael Fox, Krista Goodman, Eric Steven Manas
  • Cancer treatment method
    Patent number: 8444988
    Abstract: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: May 21, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Karen Elizabeth Lackey, Robert J. Mullin, Neil Spector, Edgar Raymond Wood, III, Wenle Xia
  • Benzimidazole derivatives as P13 kinase inhibitors
    Patent number: 8435988
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: May 7, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph Rivero, Robert Sanchez, Rosanna Tedesco
  • Inhibitors of Akt activity
    Patent number: 8420690
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: April 16, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark Andrew Seefeld, Meagan B. Rouse
  • Inhibitors of Akt activity
    Patent number: 8410158
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: April 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding